Leap Therapeutics Correlations
LPTX Stock | USD 2.98 0.06 2.05% |
The current 90-days correlation between Leap Therapeutics and X4 Pharmaceuticals is 0.12 (i.e., Average diversification). The correlation of Leap Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Leap Therapeutics Correlation With Market
Average diversification
The correlation between Leap Therapeutics and DJI is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Leap Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Leap |
Moving together with Leap Stock
Moving against Leap Stock
0.49 | ELAN | Elanco Animal Health | PairCorr |
0.47 | ZTS | Zoetis Inc | PairCorr |
0.34 | HLN | Haleon plc | PairCorr |
0.33 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.64 | CTLT | Catalent | PairCorr |
0.56 | ANRO | Alto Neuroscience, | PairCorr |
0.55 | CVS | CVS Health Corp Sell-off Trend | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Leap Stock performing well and Leap Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Leap Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
XFOR | 5.02 | (0.47) | 0.00 | (0.22) | 0.00 | 8.82 | 62.35 | |||
TERN | 3.37 | (0.33) | 0.00 | (0.22) | 0.00 | 6.02 | 34.09 | |||
DAWN | 2.06 | (0.09) | (0.04) | 0.01 | 2.77 | 3.84 | 11.44 | |||
PDSB | 3.37 | (0.63) | 0.00 | (0.24) | 0.00 | 7.67 | 31.83 | |||
INZY | 2.76 | (1.22) | 0.00 | (0.59) | 0.00 | 5.07 | 16.62 | |||
EFTR | 7.57 | (5.30) | 0.00 | (0.79) | 0.00 | 8.70 | 88.91 | |||
ELEV | 3.46 | (0.37) | 0.00 | (0.05) | 0.00 | 5.77 | 22.21 | |||
MREO | 2.72 | (0.48) | 0.00 | (0.30) | 0.00 | 4.80 | 17.36 | |||
HEPA | 3.78 | (0.37) | 0.00 | (0.09) | 0.00 | 8.06 | 33.54 | |||
HOOK | 2.81 | (1.14) | 0.00 | (1.07) | 0.00 | 6.85 | 22.98 |
Leap Therapeutics Corporate Management
Augustine Lawlor | Chief Officer | Profile | |
Cynthia MD | Chief Officer | Profile | |
Christine Granfield | VP Quality | Profile | |
Mark OMahony | Chief Officer | Profile | |
Jason Baum | Chief Officer | Profile | |
Cynthia Sirard | Chief Officer | Profile |